55 active not recruiting, 24 completed, 10 recruiting, 6 terminated. 71 Phase 2, 47 Phase 1, 1 Not applicable.
Follow Refractory Malignant Solid Neoplasm: new trials by email Literature Review of Refractory Malignant Solid Neoplasm trials Research Report on Refractory Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 | Recruiting | Mayo Clinic | 42 | 2025-11-07 | 2026-09-24 |
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Recruiting | Anusha Kalbasi | 18 | 2025-10-07 | 2026-03-17 |
| Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma Bcl-XL Proteolysis Targeting Chimera DT2216, Biospecimen Collection, Irinotecan - Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma | Phase 1 / Phase 2 | Suspended | Children's Oncology Group | 81 | 2025-06-12 | 2026-08-24 |
| Studying TAK-243 in Patients With Advanced Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 95 | 2025-03-24 | 2026-10-13 |
| Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors Axatilimab, Biopsy, Biospecimen Collection - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 / Phase 2 | Recruiting | OHSU Knight Cancer Institute | 38 | 2024-05-21 | 2026-07-08 |
| Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2023-07-14 | 2026-08-04 |
| AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Cholangiocarcinoma, Advanced Hepatocellular Carcinoma | Phase 1 | Suspended | University of Southern California | 36 | 2023-03-29 | 2026-08-17 |
| Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Atezolizumab, Biospecimen Collection, Computed Tomography - Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 86 | 2022-11-17 | 2026-07-14 |
| Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors BET Bromodomain Inhibitor ZEN-3694, Computed Tomography, Core Biopsy - Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 49 | 2022-11-16 | 2026-07-15 |
| Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment Best Practice, Chart Abstraction, Educational Intervention - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Not applicable | Active not recruiting | SWOG Cancer Research Network | 1284 | 2022-10-14 | 2026-01-22 |
| AOH1996 for the Treatment of Refractory Solid Tumors PCNA Inhibitor AOH1996 - Refractory Malignant Solid Neoplasm, Osteosarcoma | Phase 1 | Recruiting | City of Hope Medical Center | 92 | 2022-09-08 | 2026-10-20 |
| Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 42 | 2022-08-02 | 2026-10-14 |
| Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) Biopsy, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2022-02-22 | 2024-05-06 | |
| Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors Cabozantinib, Pamiparib - Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 44 | 2022-02-09 | 2026-05-12 |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Diffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 63 | 2022-01-28 | 2026-09-11 |
| Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors Elimusertib - Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 31 | 2021-12-22 | 2026-01-23 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint - Colorectal Carcinoma, Endometrial Carcinoma | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 147 | 2021-11-08 | 2026-08-25 |
| Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors anti-MESO CAR T cells - Refractory Malignant Solid Neoplasm | Phase 1 | Unknown | Ruijin Hospital | 12 | 2021-10-01 | 2021-09-17 |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Onivyde, Talazoparib, Temozolomide - Recurrent Solid Tumor, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 90 | 2021-06-09 | 2026-05-19 |
| Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study Biospecimen Collection, Ipilimumab, Nivolumab - Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2021-05-11 | 2026-06-10 |
Showing 20 of 102. Sign in to see all of them.
Lymphoma (44) · Multiple Myeloma (35) · Hematologic Neoplasms (23) · Neuroblastoma (19) · Central Nervous System Neoplasms (18) · Neoplasm Metastasis (18) · Osteosarcoma (16) · Lymphoma, Non-Hodgkin (15) · Rhabdomyosarcoma (15) · Hepatoblastoma (14) · Neuroectodermal Tumors, Primitive, Peripheral (14) · Sarcoma (14) · Wilms Tumor (14) · Glioma (13) · Rhabdoid Tumor (13)
Neoplasms (95) · Neoplasms by Histologic Type (76) · Neoplasms by Site (64) · Hemic and Lymphatic Diseases (59) · Immune System Diseases (59) · Immunoproliferative Disorders (59) · Lymphatic Diseases (59) · Lymphoproliferative Disorders (59) · Hematologic Diseases (37) · Blood Protein Disorders (35) · Cardiovascular Diseases (35) · Hemorrhagic Disorders (35) · Hemostatic Disorders (35) · Neoplasms, Plasma Cell (35) · Paraproteinemias (35)
Specimen Handling (38) · Biopsy (30) · Magnetic Resonance Spectroscopy (30) · X-Rays (12) · Nuclear Medicine Department, Hospital (10) · Phantoms, Imaging (8) · trametinib (8) · Crizotinib (6) · Nivolumab (6) · palbociclib (6) · Irinotecan (5) · Paclitaxel (5) · Taxes (5) · adavosertib (5) · olaparib (5)
National Cancer Institute (NCI) (72) · Children's Oncology Group (9) · M.D. Anderson Cancer Center (9) · Mayo Clinic (2) · OHSU Knight Cancer Institute (2) · University of Southern California (2) · Anusha Kalbasi (1) · City of Hope Medical Center (1) · Ruijin Hospital (1) · SWOG Cancer Research Network (1) · Sameek Roychowdhury (1) · St. Jude Children's Research Hospital (1)
United States (99) · Puerto Rico (14) · Canada (10) · Australia (6) · China (1) · Guam (1)
Siqing Fu (4) · David S Hong (3) · Filip Janku (3) · Patricia M LoRusso (3) · Aung Naing (2) · Jason J Luke (2) · John L Hays (2) · Julia Glade-Bender (2) · Kevin M Kalinsky (2) · Michael V Ortiz (2) · Nilofer S Azad (2) · Sarah Shin (2) · Sarina A Piha-Paul (2) · Shivaani Kummar (2) · Timothy A Yap (2)
PMID 31401903, PMID 32463741, PMID 39863139, PMID 23598171, PMID 26586415, PMID 28032129, PMID 31765263, PMID 32192573, PMID 33048619, PMID 33568345, PMID 33591402, PMID 33881209, PMID 34486544, PMID 35133871, PMID 35138919, PMID 35353553, PMID 35363510, PMID 36351402, PMID 36469840, PMID 37036756, PMID 37053535, PMID 37314501, PMID 37322121, PMID 37934000, PMID 38270822, PMID 38520670, PMID 38591867, PMID 38815151, PMID 38873934, PMID 38935895, PMID 39487711, PMID 39666929, PMID 39693587, PMID 39913886, PMID 39998620, PMID 39998852, PMID 40139261, PMID 40153687, PMID 40865033, PMID 41066729, PMID 41118283, PMID 41166674, PMID 41533998, PMID 41556942, PMID 41646361, PMID 41920422, PMID 42686334, PMID 42867148
U10CA180820 (37), U24CA196172 (21), U10CA180886 (13), UM1CA097452 (10), UM1CA186689 (5), UM1CA228823 (5), UM1CA186688 (4), P30CA016672 (3), P30CA014089 (2), UM1CA186717 (2), P30CA006516 (1), P30CA015083 (1), P30CA015704 (1), P30CA033572 (1), P30CA072720 (1)